

Supplementary Materials

Computationally Assisted Lead Optimization of Novel Potent and Selective MAO-B Inhibitors

Vedanjali Gogineni ^{1,2}, Manal A. Nael ^{3,4,†}, Narayan D. Chaurasiya ^{5,6,†}, Khaled M. Elokely ^{3,4}, Christopher R. McCurdy ^{1,7}, John M. Rimoldi ¹, Stephen J. Cutler ^{1,8}, Babu L. Tekwani ^{5,6,*} and Francisco León ^{1,8,*}

- ¹ Department of BioMolecular Sciences, Division of Medicinal Chemistry, University of Mississippi, Oxford, MS 38677, USA; gogineni@musc.edu (V.G.); cmccurdy@cop.ufl.edu (C.R.M.); jrimoldi@olemiss.edu (J.M.R.); sjcutler@cop.sc.edu (S.J.C.)
- ² Affiliate Instructor, Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA
- ³ Department of Chemistry and ICMS, Temple University, Philadelphia, PA 19122, USA; manal.nael@temple.edu (M.A.N.); kelokely@temple.edu (K.M.E.)
- ⁴ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt
- ⁵ Division of Drug Discovery, Southern Research, Birmingham, AL 35205, USA; nchaurasiya@southernresearch.org
- ⁶ National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, University of Mississippi, Oxford, MS 38677, USA
- ⁷ Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
- ⁸ Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA
- * Correspondence: btekwani@southernresearch.org (B.L.T.); jleon@mailbox.sc.edu (F.L.)
- † These authors contributed equally to this study.

Table of Contents	Pages
Suppl. Figures S1-S3. Spectra for compound 1a	S3-S4
Suppl. Figures S4-S6. Spectra for compound 1b	S4-S5
Suppl. Figures S7-S10. Spectra for compound 1c	S6-S7
Suppl. Figures S11-S13. Spectra for compound 2a	S8-S9
Suppl. Figures S14-S16. Spectra for compound 2b	S9-S10
Suppl. Figures S17-S20. Spectra for compound 2c	S11-S12
Suppl. Figures S21-S23. Spectra for compound 3a	S13-S14
Suppl. Figures S24-S26. Spectra for compound 3b	S14-S15
Suppl. Figures S27-S30. Spectra for compound 3c	S16-S17
Suppl. Figures S31-S33. Spectra for compound 4a	S18-S19
Suppl. Figures S34-S36. Spectra for compound 4b	S19-S20
Suppl. Figures S37-S40. Spectra for compound 4c	S21-S22
Suppl. Figures S41-S43. Spectra for compound 5a	S23-S24
Suppl. Figures S44-S46. Spectra for compound 5b	S24-S25
Suppl. Figures S47-S49. Spectra for compound 6a	S26-S27
Suppl. Figures S50-S52. Spectra for compound 6b	S27-S28
Suppl. Figures S53-S55. Spectra for compound 6c	S29-S30
Suppl. Figures S56-S59. Spectra for compound 6d	S30-S32
Suppl. Figures S60-S62. Spectra for compound 7c	S32-S33
Suppl. Figures S63-S66. Spectra for compound 7d	S34-S35
Suppl. Figures S67-S70. Spectra for compound 8d	S36-S37
Computational interactions of acacetin and MAO A and MAO B	S38-S340
Suppl. Figure S71. Protein-ligand RMSD	S38
Suppl. Figure S72. Interaction profile of acacetin in MAO-A	S39
Suppl. Figure S73. Interaction profile of acacetin in MAO-B	S40
Suppl Figure S74. Protein and ligand RMSD	S41
Suppl Figure S75. Protein-ligand contacts and their interaction fractions for pose 1 (A) and pose 2 (B) for acacetin 7- <i>O</i> -methyl ether	S41
Suppl Figure S76. Dose-response profile for in vitro inhibition of recombinant human MAO-B by deprenyl, acacetin, and potent acacetin 7- <i>O</i> -methyl ether analogs (1-4) c (% activity vs concentration)	S42
Suppl Figure S77. Time-dependent inhibition of recombinant human MAO-B by Deprenyl, acacetin, 1c, 2c, 3c and 4c	S42
Suppl Table S1. Docking scores of acacetin 7- <i>O</i> -methyl ether analogs	S43
Suppl. Table S2. ADME predictions for acacetin analogs	S44




Figure S1. ¹H NMR spectrum of chalcone (1a) in CDCl₃, 400 MHz




Figure S2. ¹³C NMR spectrum of chalcone (1a) in CDCl₃, 100 MHz




Figure S3. ESIMS spectrum of chalcone (1a).




Figure S4. ^1H NMR spectrum of flavonoid (1b) in CDCl_3 , 400 MHz




Figure S5. ¹³C NMR spectrum of flavonoid (1b) in CDCl₃, 100 MHz




Figure S6. ESIMS spectrum of flavonoid (1b).




Figure S7. ¹H NMR spectrum of flavonoid (1c) in CDCl₃, 400 MHz




Figure S8. ¹³C NMR spectrum of flavonoid (1c) in CDCl₃, 100 MHz




Figure S9. ESIMS of flavonoid (1c).




Figure S10. HPLC analysis of flavonoid (1c).




Figure S11. ¹H NMR spectrum of chalcone (2a) in CDCl₃, 400 MHz




Figure S12. ¹³C NMR spectrum of chalcone (2a) in CDCl₃, 100 MHz




Figure S13. ESIMS spectrum of chalcone (2a).




Figure S14. ^1H NMR spectrum of flavonoid (2b) in CDCl_3 , 400 MHz




Figure S15. ¹³C NMR spectrum of flavonoid (2b) in CDCl₃, 100 MHz




Figure S16. ESIMS spectrum of flavonoid (2b).




Figure S17. ¹H NMR spectrum of flavonoid (2c) in CDCl₃, 400 MHz




Figure S18. ¹³C NMR spectrum of flavonoid (2c) in CDCl₃, 100 MHz




Figure S19. ESIMS spectrum of flavonoid (2c).




Figure S20. HPLC analysis of flavonoid (2c).




Figure S21. ¹H NMR spectrum chalcone (3a) in CDCl₃, 500 MHz




Figure S22. ¹³C NMR spectrum of chalcone (3a) in CDCl₃, 125 MHz




Figure S23. ESIMS spectrum of chalcone (3a).




Figure S24. ^1H NMR spectrum of flavonoid (3b) in CDCl_3 , 400 MHz




Figure S25. ^{13}C NMR spectrum of flavonoid (3b) in CDCl_3 , 100 MHz




Figure S26. ESIMS spectrum of flavonoid (3b).




Figure S27. ¹H NMR spectrum of flavonoid (3c) in CDCl₃, 400 MHz




Figure S28. ¹³C NMR spectrum of flavonoid (3c) in CDCl₃, 100 MHz




Figure S29. ESIMS spectrum of flavonoid (3c).




Figure S30. HPLC analysis of flavonoid (3c).




Figure S31. ^1H NMR spectrum of chalcone (4a) in CDCl_3 , 500 MHz




Figure S32. ^{13}C NMR spectrum of chalcone (4a) in CDCl_3 , 125 MHz




Figure S33. ESIMS spectrum of chalcone (4a).




Figure S34. ^1H NMR spectrum of flavonoid (4b) in CDCl_3 , 400 MHz




Figure S35. ¹³C NMR spectrum of flavonoid (4b) in CDCl₃, 100 MHz




Figure S36. ESIMS spectrum of flavonoid (4b).




Figure S37. ¹H NMR spectrum of flavonoid (4c) in CDCl₃, 400 MHz




Figure S38. ¹³C NMR spectrum of flavonoid (4c) in CDCl₃, 100 MHz




Figure S39. ESIMS spectrum of flavonoid (4c).




Figure S40. HPLC analysis of flavonoid (4c).




Figure S41. ¹H NMR spectrum of chalcone (5a) in CDCl₃, 400 MHz




Figure S42. ¹³C NMR spectrum of chalcone (5a) in CDCl₃, 100 MHz




Figure S43. ESIMS spectrum of flavonoid (5a).




Figure S44. ^1H NMR spectrum of flavonoid (5b) in CDCl_3 , 400 MHz




Figure S45. ¹³C NMR spectrum of flavonoid (5b) in CDCl₃, 100 MHz




Figure S46. ESIMS spectrum of flavonoid (5b).




Figure S47. ¹H NMR spectrum of chalcone (6a) in CDCl₃, 400 MHz




Figure S48. ¹³C NMR spectrum of chalcone (6a) in CDCl₃, 100 MHz




Figure S49. ESIMS spectrum of chalcone (6a).




Figure S50. ^1H NMR spectrum of flavonoid (6b) in CDCl_3 , 400 MHz




Figure S51. ^{13}C NMR spectrum of flavonoid (6b) in CDCl_3 , 100 MHz




Figure S52. ESIMS spectrum of flavonoid (6b).




Figure S53. ¹H NMR spectrum of flavonoid (6c) in CDCl₃, 500 MHz




Figure S54. ¹³C NMR spectrum of flavonoid (6c) in CDCl₃, 125 MHz



Figure S55. ESIMS spectrum of flavonoid (6c).




Figure S56. ^1H NMR spectrum of flavonoid (6d) in CDCl_3 , 500 MHz




Figure S57. ¹³C NMR spectrum of flavonoid (6d) in CDCl₃, 125 MHz




Figure S58. ESIMS spectrum of flavonoid (6d).




Figure S59. HPLC analysis of flavonoid (6d).




Figure S60. ^1H NMR spectrum of flavonoid (7c) in CDCl_3 , 400 MHz




Figure S61. ¹³C NMR spectrum of flavonoid (7c) in CDCl₃, 100 MHz




Figure S62. ESIMS spectrum of flavonoid (7c).




Figure S63. ^1H NMR spectrum of flavonoid (7d) in CDCl_3 , 500 MHz




Figure S64. ^{13}C NMR spectrum of flavonoid (7d) in CDCl_3 , 125 MHz




Figure S65. ESIMS spectrum of flavonoid (7d).




Figure S66. HPLC analysis of flavonoid (7d).




Figure S67. ^1H NMR spectrum of flavonoid (8d) in CDCl_3 , 500 MHz




Figure S68. ^{13}C NMR spectrum of flavonoid (8d) in CDCl_3 , 125 MHz




Figure S69. ESIMS spectrum of flavonoid (8d)




Figure S70. HPLC analysis of flavonoid (8d).

Computational Interactions of Acacetin and MAO-A and MAO-B

To understand the binding behavior of acacetin in MAO-A and MAO-B binding sites, a long molecular dynamics (MD) simulation study (200 ns) was conducted. The interaction profile and the average changes in the heavy atom displacement of acacetin (Figure S71) were monitored over the course of the MD simulations time with respect to the original frame using the following equation:

$$RMSD_x = \sqrt{\frac{1}{N} \sum_{i=1}^N (r'_i(t_x) - r_i(t_{ref}))^2}$$

Frame x is recorded at time t_x ; $RMSD_x$ is the root mean square deviation of selected atoms in frame x; N is the number of atoms; t_{ref} is the reference time; r'_i is the position of the selected atom (i) after aligning on the reference frame.




Figure S71. Protein-ligand RMSD. Top: RMSD of MAO-B. Bottom: RMSD of MAO-A.

Acacetin displayed stable binding in MAO-B with an average RMSD of 2.8 Å for the protein backbone and 6.0 Å for the ligand (Figure S71, top), while it has an average RMSD of 6.4 Å for MAO-A backbone and 2.4 Å for the ligand (Figure S71, bottom). Several prominent interactions were traced and averaged over the MD simulations. With MAO-A (Figure S72), there are two strong and highly abundant (over 95% of the MD simulations time) hydrogen bonds between the flavone hydroxyl group and Asn 181, and Tyr 444. These two hydrogen bonds are in the negative free energy

region of the water density calculations. Interrupting these interactions with bulkier and hydrophobic substituents would decrease binding to MAO-A. At the same position of MAO-B, there is one strong hydrogen bond with Thr 174 and π - π stacking with Tyr 398 (Figure S73). Modifying acacetin to have small hydrophobic groups at this position (R_1) should not alter MAO-B activity. In general, acacetin has stronger hydrogen bonds and more polar contacts with MAO-A, and more hydrophobic contacts with MAO-B (Figures S72-73).

Protein-Ligand Contacts




Figure S72 Interaction profile of acacetin in MAO-A.

Protein-Ligand Contacts





Figure S73. Interaction profile of acacetin in MAO-B.




Figure S74. Protein and ligand RMSD. Top: RMSD of pose 1. Bottom: RMSD of pose 2 for acacetin 7-*O*-methyl ether.




Figure S75. Protein-ligand contacts and their interaction fractions for pose 1 (A) and pose 2 (B) for acacetin 7-*O*-methyl ether.




Figure S76. Dose-response profile for in vitro inhibition of recombinant human MAO-B by deprenyl, acacetin, and potent acacetin 7-*O*-methyl ether analogs (**1-4**) **c** (% activity vs concentration).




Figure S77. Time-dependent inhibition of recombinant human MAO-B by Deprenyl (0.075 μM), acacetin (0.080 μM), **1c** (0.100 μM), **2c** (0.300 μM), **3c** (0.300 μM), and **4c** (0.400 μM). Each point represents mean \pm S.D. of triplicate values.

Table S1. Docking scores of acacetin 7-*O*-methyl ether analogs

Compound	MAO-A Docking score [kcal/mol]	MAO-B Docking score [kcal/mol]
1c	-3.511	-15.243
2c	-3.650	-15.102
3c	-2.732	-15.663
4c	-4.661	-15.545
5c	-5.434	-16.172
6d	-5.871	-15.451
7d	-3.221	-14.912
8d	-4.761	-16.084
Acacetin	-6.2	-8.1
Acacetin 7-<i>O</i>-methyl ether	-6.7	-8.9

Table S2. ADME Predictions for Acacetin Analogs

Compound	MW	SASA	QPlogPo/w	QPlogS	% Human oral absorption	PSA	#N and O	Rule of five	Rule of three
1c	326.348	618.778	4.020	-5.166	100.000	70.522	5	0	0
2c	326.348	611.087	3.963	-5.183	100.000	70.582	5	0	0
3c	340.375	640.381	4.359	-5.575	100.000	69.728	5	0	0
4c	322.317	592.458	3.835	-4.913	100.000	70.872	5	0	0
5c	338.359	637.061	4.249	-5.512	100.000	70.886	5	0	0
6d	325.363	621.141	3.834	-5.322	100.000	75.690	5	0	0
7d	325.363	612.923	3.797	-5.337	100.000	75.196	5	0	0
8d	337.374	639.249	4.059	-5.646	100.000	76.089	5	0	0
Acacetin	284.268	513.480	2.461	-3.824	87.477	85.418	5	0	0
Acacetin 7-O-methyl ether	298.295	537.958	3.141	-3.960	100.000	71.054	5	0	0
Harmine	212.251	444.308	3.082	-3.550	100.000	33.445	3	0	0
Deprenyl	187.284	454.187	2.993	-1.854	100.000	5.098	1	0	0
Clorgyline	272.174	547.929	4.044	-3.558	100.000	12.399	2	0	0

*MW: Molecular Weight; SASA: Solvent Accessible Surface Area; QPlogPo/w: Predicted octanol / water partition coefficient (Recommended values –2.0 to 6.5); QPlogS: Predicted aqueous solubility (log S Recommended values –6.5 to 0.5); PSA: Polar Surface Area.